{"id":"NCT05048342","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines","officialTitle":"A Multicenter, Open-label Phase 3 Study of Remibrutinib (LOU064) to Investigate the Safety, Tolerability and Efficacy for 52 Weeks in Adult Japanese Chronic Spontaneous Urticaria Patients Inadequately Controlled by H1-antihistamines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-01-15","primaryCompletion":"2023-12-08","completion":"2023-12-09","firstPosted":"2021-09-17","resultsPosted":"2024-11-22","lastUpdate":"2025-04-08"},"enrollment":71,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"DRUG","name":"LOU064","otherNames":["remibrutinib"]}],"arms":[{"label":"LOU064 25 mg b.i.d.","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to evaluate the safety, tolerability and efficacy of remibrutinib (LOU064) in adult Japanese patients chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment by H1-antihistamine (H1-AH) at locally label approved doses, for a duration of 52 weeks of treatment with remibrutinib and a post-treatment follow-up period of up to 4 weeks.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events","timeFrame":"Baseline up to 30 days after last dose of study medication, assessed up to approximately 56 weeks","effectByArm":[{"arm":"LOU064 25 mg b.i.d.","deltaMin":62,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":13,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=2425"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":71},"commonTop":["COVID-19","Headache","Nasopharyngitis","Dermatitis atopic","Diarrhoea"]}}